Randi Hernandez

Pfizer will pay $850 million upfront and as much as $2 billion later in a deal to jointly develop one of Merck?s cancer drugs.

Avastin plus chemotherapy for the treatment of ovarian cancer increased progression-free survival by 62% compared with chemotherapy alone.

After being plagued by numerous delays, Lemtrada (alemtuzumab) has finally been approved by FDA for the treatment of multiple sclerosis.

The transaction provides Allergan stockholders with immediate value and enhanced commercial opportunities, according to a company statement.

New technologies facilitate enhanced single-use processes and procedures.

An increased need for higher-capacity resins and the demand for smaller batches has made disposable chromatography a more viable option.

Representatives from industry supplier companies address innovations, reliability, barriers to adoption, and the role of singIe-use bioreactors in bioprocessing.

The new location will increase Bristol-Myers Squibb's biologics manufacturing capacity.

The new partnership will focus on RNA biology for the discovery and manufacture of new therapies.

Amgen's Phase III candidate for the treatment of psoriasis was found to clear skin lesions better than Johnson & Johnson's Stelara.

ANSM wants company data on the benefits and risks of using Avastin over Lucentis in the treatment of wet age-related macular degeneration.

The deal between the two companies will strengthen Perrigo's presence in Europe.

Amgen wants the regulatory agency to ensure biosimilar applicants follow the rules of the patent dispute resolution process delineated by the BPCIA.

M&A transactions accounted for nearly $15 billion more this year than for the same period a year ago.

Amgen is suing Sandoz over Sandoz's biosimilar application for filgrastim.

The final guidance explains some principles for developing biosimilars and establishes some rules about extrapolation across indications for various medical conditions.

The company receives backing to continue its work in research services, process development, and cGMP manufacturing activities.

The Yale School of Medicine and Gilead will continue their research on cancer targets for a minimum of three additional years.

New research will focus on a superfamily of protein receptors linked to various diseases.

The divestment will create the number two player in the global influenza vaccine industry.

Two lots of empty intravenous fluid bags were voluntarily recalled because of the presence of particulates.

Shire announces it will expand its orphan drug portfolio and is ready for future M&A discussions.

Celgene expands its oncology drug discovery and development portfolio through a new partnership with Sutro.

The latest Ebola epidemic sheds light on the delicate processes surrounding the manufacture of genetically modified live cells for biopharmaceutical production.

Secukinumab is the first IL-17A inhibitor to meet its primary endpoint in two Phase III trials for patients with ankylosing spondylitis.

The renovation to Roche's historic office building in Basel, Switzerland will feature sustainable workplaces and a state-of-the-art research center.

An advisory committee recommends use of the first psoriasis therapy targeting IL-17A.

A Priority Review voucher Sanofi and Regeneron purchased from BioMarin pharmaceuticals may put their mAb ahead of Amgen's in the market.

The new service offering will help customers determine levels of permeability, transport, metabolism, and toxicity in drug product.

Personalized immunotherapy treatments help 90% of acute lymphoblastic leukemia patients achieve remission in a new study.